EXAS Stock Price Prediction

Exact Sciences Corp

EXAS

Exact Sciences Corp

45.000

+1.960(+4.550%)

EXAS Price Prediction Next Week

Analysis and Insights

To predict the stock price of Exact Sciences (EXAS) for the next trading week, we analyze both news sentiment and technical indicators.

News Sentiment Analysis:

Analyst Ratings: Piper Sandler lowered the price target for EXAS from $75 to $70 while maintaining an Overweight rating. Scotiabank raised the price target to $73, while BTIG lowered it to $65, indicating mixed analyst sentiment.
Ark Invest's Action: Ark Invest sold 80,270 shares of EXAS, reflecting a notable reduction in their position.
Investor Conferences: EXAS is scheduled to participate in March investor conferences, which could positively impact sentiment.

Technical Analysis:

RSI: The RSI for EXAS is 35.42, indicating oversold conditions.
MACD: The MACD is negative (-1.86), signaling bearish momentum.
SMA: The stock is trading below its 20, 50, and 200-day moving averages.
Fibonacci Levels: Resistance levels at $51.01 and $52.51, with support at $46.14 and $44.64.

Price Prediction:

Based on the oversold RSI and potential positive news from investor conferences, EXAS may experience a short-term rebound. The price target for next week is $48.50.

Recommendation:

Buy EXAS at the current price of $46.51, anticipating a rebound toward the $48.50 level.

Analysis and Insights

To predict the stock price of Exact Sciences (EXAS) for the next trading week, we analyze both news sentiment and technical indicators.

News Sentiment Analysis:

Analyst Ratings: Piper Sandler lowered the price target for EXAS from $75 to $70 while maintaining an Overweight rating. Scotiabank raised the price target to $73, while BTIG lowered it to $65, indicating mixed analyst sentiment.
Ark Invest's Action: Ark Invest sold 80,270 shares of EXAS, reflecting a notable reduction in their position.
Investor Conferences: EXAS is scheduled to participate in March investor conferences, which could positively impact sentiment.

Technical Analysis:

RSI: The RSI for EXAS is 35.42, indicating oversold conditions.
MACD: The MACD is negative (-1.86), signaling bearish momentum.
SMA: The stock is trading below its 20, 50, and 200-day moving averages.
Fibonacci Levels: Resistance levels at $51.01 and $52.51, with support at $46.14 and $44.64.

Price Prediction:

Based on the oversold RSI and potential positive news from investor conferences, EXAS may experience a short-term rebound. The price target for next week is $48.50.

Recommendation:

Buy EXAS at the current price of $46.51, anticipating a rebound toward the $48.50 level.

EXAS Similar Chart Price Prediction

The price of EXAS is predicted to go up 1.08%, based on the high correlation periods with HURC. The similarity of these two price pattern on the periods is 98.85%.

EXAS

Future prediction

Up: 1.08%

HURC

Up: 1.08%Similarity: 98.85%

EXAS Revenue Forecast

EXAS EPS Forecast

EXAS FAQs

What is EXAS revenue forecast for next quarter？

The market consensus for EXAS's revenue in the upcoming quarter is projected to be approximately $689.785M USD.

What is EXAS eps forecast for next quarter？

EXAS VS S&P500

Exact Sciences Corp

SPDR S&P 500

Cologuard's staying power is underappreciated. It could take years for liquid biopsy to steal share, and Cologuard's market share could soar past 10%.

Exact is positioned for growth regardless of how liquid biopsies play out, and the firm's liquid biopsy initiative is a good hedge in case Cologuard feels competitive pressure.

Exact has a robust pipeline of liquid biopsy offerings, including minimal residual disease (MRD), multicancer early detection (MCED), and CRC screening.

Ask Intellectia about EXAS

EXAS Analyst's Forecast

Gerard Cassidy

RBC Capital

Hold

2025-03-13

Price Target

$52

Upside

+20.82%

RBC Capital initiated coverage of Exact Sciences with a Sector Perform rating and $52 price target while launching coverage of the Liquid Biopsy space. Exact is the leader in colorectal cancer with its at-home test, Cologuard, the analyst noted. While it has had success displacing traditional screening methods for CRC, new competitive entrants are likely to dampen Exact's growth going forward and the stool-based testing method does not transfer over to other areas of cancer testing so the firm contends that it is unclear if the company will have success with its upcoming product launches.